GAAPP and the EoE Day Alliance Announce the Launch of the First-Ever World EoE Day on May 22
World EoE Day is made possible through the EoE Day Alliance, a collaborative effort between leading patient organizations from Austria, Australia, Italy, Serbia, Spain, The United Kingdom and The United States of America.
Together, the Alliance aims to:
Raise Awareness: Educate the global public about EoE, its symptoms, and the importance of early diagnosis.
Encourage Medical Consultation: Empower individuals experiencing symptoms such as difficulty swallowing, food impaction, chest pain, or persistent reflux-like symptoms to seek medical advice.
Advocate for Better Care and Treatment: Call for improved access to medical care, novel treatments, and research funding to improve the quality of life of EoE patients worldwide.
Support LMICs: Push for increased investment in research, advocacy, and medical education, especially in regions where EoE remains largely overlooked.
'EoE is often misunderstood or misdiagnosed, leaving many patients suffering without proper treatment. By launching World EoE Day, we hope to bring much-needed attention to this condition and advocate for change on a global scale,' said Víctor Gascón Moreno, Vice President of Awareness and Operations at GAAPP.
'Raising awareness about eosinophilic esophagitis is critical to ensuring early diagnosis and access to appropriate care. Too many patients endure years of symptoms before receiving answers. By increasing understanding among healthcare providers and the public, we can reduce delays in recognition and diagnostics, improve outcomes, and enhance the quality of life for those affected by this chronic condition,' said Mary Jo Strobel, Executive Director at APFED.
'Celebrating World Eosinophilic Esophagitis Day is a significant step in our fight, as it allows us to raise awareness about this disease, strengthen mutual support, and consolidate our efforts to educate, support, and advocate for the rights of all those affected in Spain, while continuing our mission to improve their quality of life,' said Zoraida Gómez Carpio, President of ADESEO and caregiver of a child living with EoE.
GAAPP and its partners invite healthcare professionals, policymakers, researchers, and the general public to join this movement by spreading awareness, engaging in discussions, and advocating for stronger support for EoE patients worldwide.
About GAAPP
Global Allergy & Airways Patient Platform is an umbrella organization founded in 2009 to bring a collective patient voice to the global conversation on atopic, allergy, and airway diseases. Today, the organization comprises more than 160 patient organizations that work to raise awareness and advocate for global policy to ensure access to care for the more than 800 million patients living with these conditions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
9 hours ago
- Associated Press
Co-Investigator of Clinical Safety Study Presents at EHA
Lexington, MA August 19, 2025 --( )-- Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, announces that the data from its safety study was accepted in the form of an oral presentation at the European Hematology Association 2025 Congress that took place in Milan, Italy on June 12-15. Co-Investigator Håkon Reikvam presented the results of the Hematological Malignancies cohort in a presentation titled 'Safety of Hypoxic Red Blood Cell Administration in Patients with Transfusion-Dependent Hematological Malignancies,' as a prelude to a larger study. The full clinical study was designed to evaluate the safety profile of hypoxic red blood cells (RBCs) in chronically transfused patients with hematologic malignancies and acutely bleeding burn patients. The study, that was completed in Q4 2024, has been submitted for publication. Håkon Reikvam, Professor at University of Bergen, Bergen, Norway, states, 'We are thrilled to share our safety findings with the medical community. This cohort analysis serves as a foundational pillar for our upcoming efficacy trials. It not only strengthens the scientific rationale behind our approach but also lays the groundwork for the next phase of our research.' The HEMANEXT ONE RBC Processing and Storage system limits oxygen, the fuel for oxidative damage, providing a higher quality blood product (1,2,3). It has the potential to benefit all patients requiring transfusions for chronic conditions, such as thalassemia (4), sickle cell disease (5), and myelodysplastic syndromes (6), as well as those in need of critical transfusions during acute bleeding in surgery, trauma and other medical procedures (7). About Hemanext Hemanext is a privately held medical technology company based in Lexington, MA, that is dedicated to improving the quality, safety, efficacy, and cost of transfusion therapy. The company's research and development efforts focus on the study of hypoxically stored RBCs. The company's aim is to significantly improve the quality of stored RBCs worldwide. Visit to learn more about the Company. About Hemanext ONE Hemanext ONE has been granted marketing authorization for commercial distribution via the De Novo process by the U.S. Food & Drug Administration. It is intended to process and store CP2D/AS-3 Red Blood Cells, Leukocytes Reduced (LR RBC) that have been prepared within the standard 8-hour hold time. Processing of Red Blood Cells processed with the HEMANEXT ONE system must be initiated within 8 hours of collection and completed within 12 hours of collection. The Red Blood Cells must be processed at room temperature (20-26°C). The HEMANEXT ONE system limits O2 and CO2 levels in the storage environment. Red Blood Cells Leukocytes Reduced, O2/ CO2 Reduced may be stored for up to 42 days at 1-6°C. HEMANEXT ONE is used for volumes no greater than 350 mL of LR RBC. In Europe, Hemanext ONE is CE marked, which allows its commercial distribution within the market of the European Economic Area. HEMANEXT ONE creates hypoxic RBCs, RBCs that have been processed to reduce oxygen and carbon dioxide content of RBCs and to maintain these levels throughout storage up to 42 days (3). Hypoxic RBCs have demonstrated positive impacts on multiple in vitro metrics of RBC quality in preclinical studies (8,9). Clinical studies are underway to determine the impact of hypoxic RBCs on patient outcomes and estimate potential cost savings from expected improvements in care and reductions in transfusion volumes (10). References 1. Rabcuka J, Blonski S, Meli A, et al. Metabolic reprogramming under hypoxic storage preserves faster oxygen unloading from stored red blood cells. Blood Adv. 2022;6(18):5415-5428. doi: 10.1182/bloodadvances.2022007774 2. Reisz JA, Wither MJ et al. Oxidative modifications of glyceraldehyde 3-phosphate dehydrogenase regulate metabolic reprogramming of stored red blood cells. 2016;128(12): e32-42. 3. HEMANEXT ONE® (Blood container set used to process and store CP2D/AS-3 Red Blood Cells, Leukocytes Reduced, and O2/CO2 Reduced) [US Instructions for Use]. Lexington, MA: Hemanext Inc. 4. Farmakis D, Porter J, Taher A, et al. 2021 Thalassemia International Federation Guidelines for the management of transfusion-dependent thalassemia. 2022;6:8. 5. Chou S, Alsawas M, Fasano R, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv. 2020;4:2. 6. Germing U, Oliva E, Hiwase D, and Almeida A. Treatment of anemia in transfusion-dependent and non-transfusion-dependent lower-risk MDS: current and emerging strategies. 2019;3(6). doi: 10.1097/HS9.0000000000000314 7. American College of Surgeons. ACS TQIP massive transfusion in trauma guidelines. ACS TQIP. 2014; 8. Yoshida T, Blair A, D'Alessandro A, et al. Enhancing uniformity and overall quality of red cell concentrate with anaerobic storage. Blood Transfus. 2017;15(2):172-81. 9. Yoshida T, McMahon E, Croxon H, et al. The oxygen saturation of red blood cell concentrates: The basis for a novel index of red cell oxidative stress. Transfusion. 2022;62(1):183-193. doi: 10.1111/trf.16715. 10. Reikvam H, Hetland G, Ezligini F, et al. Safety of hypoxic red blood cell administration in patients with transfusion-dependent hematological malignancies: An interim analysis. Transfus Apher Sci. 2023; doi: 10.1016/ Contact Information: Hemanext Robert Haime, Vice President, Commercial (781) 301-7474 Contact via Email Read the full story here: Co-Investigator of Clinical Safety Study Presents at EHA Press Release Distributed by
Associated Press
16 hours ago
- Associated Press
Poriferous, LLC Achieves Coveted EU MDR Regulatory Certification for Porous Polyethylene Implants
Newnan, GA August 18, 2025 --( )-- Poriferous LLC., industry innovator in high density porous polyethylene craniomaxillofaical implants, announces it has successfully received its EU Medical Device Regulation (MDR) certification. This regulatory authorization has been achieved by only 15% of medical device companies, putting Poriferous and their SU-POR® line of products in esteemed company. The certification testifies to Poriferous' rigorous standards for safety and quality, ensuring their devices have no negative impacts on human health. The EU MDR replaces the former Medical Device Directive (MDD) and establishes a more intensive and transparent regulatory framework with greater long-term viability. It emphasizes post-market surveillance, implements Unique Device Identifications (UDIs) to track devices in the supply chain, and specifically includes devices that may not have a strictly medical function, such as implants used in cosmetic surgeries. Because of these additions to the regulatory standards, Poriferous' SU-POR Implants are now included in this new, enhanced system for regulatory quality. The MDR certification covers the entire Poriferous catalogue of SU-POR Implants, reaffirming Poriferous' mission of providing quality healthcare and innovation to surgeons and patients around the world. Contact Information: Poriferous, LLC Krista Bradstreet 470-699-8608 Contact via Email Read the full story here: Poriferous, LLC Achieves Coveted EU MDR Regulatory Certification for Porous Polyethylene Implants Press Release Distributed by
Yahoo
5 days ago
- Yahoo
US eosinophilic oesophagitis market to reach $1.19bn by 2030
The eosinophilic oesophagitis (EoE) market in the US is forecast to grow from $202 million in 2020 to $1.19 billion in 2030, representing a robust compound annual growth rate of 19.4%, according to GlobalData. This growth will be fueled by the shift from off-label treatments such as proton pump inhibitors and compounded topical corticosteroids, towards more patient-friendly, US Food and Drug Association-approved therapies such as Sanofi/Regeneron's Dupixent (dupilumab), Takeda's Eohilia (budesonide oral suspension and Ellodi Pharmaceuticals' late-stage pipeline agent, APT-1011, an orally disintegrating tablet (ODT). Dupixent, first approved for EoE in adults and adolescents in 2022 then expanded in 2024 to treat children as young as one, has quickly established itself as a first-line biologic due to its strong efficacy, favourable safety profile and biweekly subcutaneous administration. Takeda's Eohilia, approved in 2024 as the first oral, targeted steroid for EoE, is expected to capture significant market share thanks to its ease of use compared to swallowed inhaler steroids. The anticipated launch of APT-1011, an ODT formulation of fluticasone propionate, will add further choice for patients, particularly in paediatrics where dosage form is a major factor in adherence. By 2030, Dupixent and Eohilia are expected to account for 75% of the US EoE market, with APT-1011 contributing 12.5%. The late-stage pipeline remains active, with more than 100 interventional trials initiated as of 2025, including novel biologics such as Amgen and AstraZeneca's co-developed Tezspire (tezepelumab), which targets upstream thymic stromal lymphopoietin (TSLP) signalling and next-generation corticosteroid formulations. Key opinion leaders interviewed by GlobalData noted a shift in clinical trial design toward multidomain endpoints that integrate histologic, endoscopic and patient-reported outcomes, moving beyond the traditional histologic remission threshold of 15 eosinophils or fewer per high-power field. This evolution reflects payer demand for more comprehensive measures of clinical benefit, particularly sustained improvement in swallowing function and quality of life. Despite the strong growth outlook, the market faces challenges. Payer step therapy and restrictive coverage criteria may limit broad adoption of biologics, while high list prices, such as Eohilia's reported launch price at approximately $5,250, could hinder uptake without robust cost-effectiveness data. Reliance on invasive endoscopy for diagnosis and monitoring also remains a significant burden, particularly in paediatric populations, though emerging tools such as the oesophageal string test and cytosponge could reduce procedure frequency. With multiple novel therapies expected to launch and the treatment paradigm shifting toward earlier, targeted intervention, GlobalData anticipates that the US EoE market will undergo rapid expansion over the forecast period, offering substantial opportunities for both biologic and small-molecule developers targeting this historically underserved condition. "US eosinophilic oesophagitis market to reach $1.19bn by 2030" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
